Document Detail


Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls.
MedLine Citation:
PMID:  17482741     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is known that 60 to 80% of schizophrenic patients show deficits in cognition. There may be an increase in these deficits as a result of additional regular use of cannabis. The aim of the study was to evaluate the effect of chronic cannabis consumption on the cognitive functions of schizophrenic patients and healthy control subjects after a minimum abstinence time of 28 days. The study sample consisted of 39 schizophrenics (19 cannabis-abusers and 20 non-abusers) and 39 healthy controls (18 cannabis-abusers, 21 non-abusers). In a 2x2-factorial design (Diagnostic Groups [healthy controls, schizophrenic patients]xCannabis abuse [without, with]) with diagnostic group and cannabis consumption considered between-subject factors) we tested the hypothesis that dually diagnosed patients (i.e. suffering both from schizophrenia and cannabis abuse) perform worse in neuropsychological tests than schizophrenic patients without cannabis abuse. On the whole, schizophrenic patients performed worse than healthy control subjects. Surprisingly, rather than deteriorating neuropsychological performance, regular cannabis abuse prior to the first psychotic episode improved cognition in some tests. This was even more pronounced when regular consumption started before the age of 17. On the other hand, cannabis use deteriorated test performance in healthy controls, especially in cases when regular consumption started before the age of 17. To sum up, regular cannabis abuse has a different effect on cognitive function in schizophrenic patients and healthy controls.
Authors:
Maria C Jockers-Scherübl; Theresa Wolf; Nicole Radzei; Peter Schlattmann; Johannes Rentzsch; Ana Gómez-Carrillo de Castro; Klaus-Peter Kühl
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-03-16
Journal Detail:
Title:  Progress in neuro-psychopharmacology & biological psychiatry     Volume:  31     ISSN:  0278-5846     ISO Abbreviation:  Prog. Neuropsychopharmacol. Biol. Psychiatry     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-31     Completed Date:  2007-08-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211617     Medline TA:  Prog Neuropsychopharmacol Biol Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  1054-63     Citation Subset:  IM    
Affiliation:
Department of Psychiatry and Psychotherapy Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, Berlin, Germany. maria.jockers@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cognition / drug effects*
Female
Humans
Intelligence Tests
Male
Marijuana Abuse / psychology*
Neuropsychological Tests
Psychiatric Status Rating Scales
Psychomotor Performance / drug effects
Schizophrenic Psychology*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anxiety and error monitoring: increased error sensitivity or altered expectations?
Next Document:  Assessment of the potential allergenicity of a Milk Basic Protein fraction.